Synthetic Artificial Blood Vessels Market

Synthetic Artificial Blood Vessels Market Outlook

Synthetic Polymers Accelerate Growth of Global Synthetic Artificial Blood Vessels Market

The global synthetic artificial blood vessels market is all set to exhibit robust revenue growth during the forecast years from 2026 to 2033. The market is poised to benefit from the growing number of life-threatening cardio and peripheral vascular cases and a growing pool of patients with unmet treatment needs. Fairfield market research indicates that the global synthetic artificial blood vessels market is valued at USD 319.4 Mn in 2026 and is projected to reach USD 470.8 Mn, growing at a CAGR of 6% by 2033.

Synthetic polymers have tunable properties, endless forms, and established structures over natural polymers. The support offered by synthetic biomaterials can enable restoration of damaged or diseased tissue structure and function.

Autologous replacement is not often available due to prior harvesting or the patient’s health. Furthermore, autologous harvesting causes secondary injury to the patient at the harvest site. Considering the limitations of natural polymers, such as cost, limited supplies, batch-to-batch variation, and cross contamination, synthetic polymers, including biodegradable polymers and non-degradable polymers, have been rapidly developed in the last decades as biomaterials.

Growing Research Activities Helps Market in a Greater Way

Growing research activities and surge in the demand for technologically advanced products have created an upward market trajectory. Seattle-based medical technology company Healionics raised a US$ 4.7 Mn round led by Keiretsu Capital to help commercialize its artificial blood vessel called STARgraft for patients who undergo dialysis treatment. The Korea Institute of Science and Technology (KIST) announced that the research team at the Biomaterials Research Center collaborated with the research team at the Organ Transplantation Center at Seoul National University to develop a bio-artificial blood vessel. Recently, researchers in Korea and Hong Kong have used a modified 3D cell printing technique to fabricate a biomimetic blood vessel that was successfully implanted in a living rat.

Growing Number of Life-Threatening Cardio and Peripheral Vascular Cases Augment Vascular Prostheses Demand

Approximately 850,000 vascular reconstruction operations in the world each year. Cardiovascular diseases, especially ones involving narrowed or blocked blood vessels with diameters smaller than 6 mm, are the leading cause of death globally. Annually, healthcare costs for patients with cardiovascular diseases exceed US$300 Bn. Approximately 6.5 million people aged 40 and older in the United States have Peripheral Arterial Disease (PAD).

Cardiovascular defects occur in 1% of live births worldwide\ and children born with them often undergo repeated surgical reconstruction as they grow. Cardiovascular disease (CVD) is the number one killer in the world, responsible for >17.3 million deaths every year, a number that represents 31% of all global deaths.

Future Belongs to Bio Artificial Blood Vessels

Humacyte is developing “bioengineered” blood vessels that can incorporate living cells after being implanted in the human body. The so-called human acellular vessels (HAVs) are experimental devices that will soon be ready for widespread use.

JOTEC GmbH, a medical device firm is developing absorbable biomaterials based on collagen: a bio artificial vascular graft in which the lumen of the vessels is coated with the patient’s own cells so that the implants replicate their natural models as closely as possible. A team of scientists in China and Switzerland developed the electronic artificial blood vessels, which are made from a flexible and biodegradable metal-polymer conductor membrane.

Plastic Grafts Don’t Check All the Boxes

The major disadvantage of synthetic biomaterials are that they lack cell adhesion sites and require chemical modifications to enhance cell adhesion. Some other disadvantages of synthetic polymers in tissue engineering applications are their poor biocompatibility, release of acidic degradation products, and loss of mechanical properties very early during degradation.

Plastic grafts still have their limitations despite intensive work put into their development. Degradation period of commonly used biodegradable synthetic polymers is significantly high (1-24 months) as against natural polymers like collagen (5 hours). The lack of transplantable vascular grafts is an unmet clinical need in the surgical treatment of CVD.

The global synthetic artificial blood vessels market study by Fairfield Market Research finds that North America remains the largest contributor in value terms due to availability of advanced technological facilities, reimbursement policies, and robust diagnostic procedures through biometric tools in the region. North America captures major chunk of the global synthetic artificial blood vessels market revenue and will reach US$120.9 Mn in 2026. Additionally, growing R&D activities in the advanced biomaterial grafts space is anticipated to create tailwinds for the synthetic artificial blood vessels market growth in the region.

Europe region also holds major chunk of market share and commendable growth during the forecast period. Growing occurrence of cardiovascular problems and aging population and the, kidney failure, aortic disease, and other health issues will benefit the regional manufacturers significantly.

Global Synthetic Artificial Blood Vessels Market: Key Players

Some of the key companies partaking in the global synthetic artificial blood vessels market are:

     • B. Braun Melsungen AG
     • Terumo Aortic (Terumo Group)
     • Humacyte, Inc.
     • LeMaitre Vascular, Inc.
     • W. L. Gore and Associates
     • JOTEC GmbH
     • Cook Medical Inc.
     • Bard Peripheral Vascular

The Global Synthetic Artificial Blood Vessels Market is Segmented as Below:

By Polymer

• Expanded polytetrafluoroethylene (ePTFE)
• Polyethylene Terephthalate
• Polyurethane
• Others

By Application

• Aortic Disease
• Hemodialysis
• Peripheral Artery Disease

By End user

• Hospitals
• Cardiac Catheterization Laboratories
• Ambulatory Surgical Centers
• Specialty Clinics

By Geographic Coverage

• North America
• Europe
• Asia Pacific
• Rest of World